Citius Pharmaceuticals (CTXR) Operating Income (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Operating Income came in at -$32.2 million in Q1 2026, down 185.9% YoY from $37.5 million in Q1 2025, and down 256.96% on a QoQ basis from -$9.0 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Operating Income (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 17 years of Operating Income data on file, last reported at -$32.2 million in Q1 2026.
- Quarterly Operating Income fell 185.9% year-over-year to -$32.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.4 million (down 35.95% YoY) and the FY2025 annual result came in at -$38.5 million, up 8.26% from the prior year.
- Operating Income fell to -$32.2 million in Q1 2026, from -$9.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$7.2 million in Q4 2022 to a low of -$32.2 million in Q1 2026.
- A 5-year average of -$10.7 million and a median of -$9.3 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2025 — Operating Income climbed 23.65% — and 2026, when it slumped 185.9%.
- Tracing CTXR's Operating Income over 5 years: stood at -$7.2 million in 2022, then fell by 28.84% to -$9.3 million in 2023, then decreased by 7.48% to -$10.0 million in 2024, then climbed by 10.16% to -$9.0 million in 2025, then tumbled by 256.96% to -$32.2 million in 2026.
- The last three Operating Income figures came in at -$32.2 million (Q1 2026), -$9.0 million (Q4 2025), and -$8.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | -11.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.19 Mn |
| Dec 31, 2025 | -9.02 Mn |
| Sep 30, 2025 | -8.44 Mn |
| Jun 30, 2025 | -8.79 Mn |
| Mar 31, 2025 | -11.26 Mn |
| Dec 31, 2024 | -10.04 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Jun 30, 2024 | -10.63 Mn |
| Mar 31, 2024 | -10.97 Mn |
| Dec 31, 2023 | -9.34 Mn |
| Sep 30, 2023 | -10.12 Mn |
| Jun 30, 2023 | -8.67 Mn |
| Mar 31, 2023 | -10.69 Mn |
| Dec 31, 2022 | -7.25 Mn |
| Sep 30, 2022 | -7.55 Mn |
| Jun 30, 2022 | -8.92 Mn |
| Mar 31, 2022 | -7.59 Mn |
| Dec 31, 2021 | -9.26 Mn |
| Sep 30, 2021 | -5.20 Mn |
| Jun 30, 2021 | -5.98 Mn |